
Colorectal cancer


- 3rd most common cancer in men and women in US
- 2nd leading cause of cancer death for men and women combined
- 5 year relative survival rate at time of diagnosis
 - 90% survival when diagnosed at stage I
 - ➤ 11% survival when diagnosed at stage IV (metastatic)
 - Only 40% of patients are diagnosed at stage I
- Enhanced screening efforts (guaiac-based fecal occult blood test – gFOBT – and colonoscopies) have led to decreased overall mortality rates in CRC, but 45% of population is not compliant with current screening guidelines
 - More user friendly screening platforms are required to enhance patient compliance with screening guidelines

Liquid biopsies






Giovanni Rizz




Methodological rigour

Add another




Initial data exploration

Year



Giovanni Rizzi

Colorectal AND Bevacizumab



Giovanni Rizzi

Status	Max Age	Min Age	Sample Size	Number of Countries	Farmaceutical	Other	Surgical
complete	99	18	1226	28	1	2	0
terminated	99	18	8	1	0	2	0

